Biogen Inc. (NASDAQ:BIIB) Shares Sold by Roberts Glore & Co. Inc. IL

Roberts Glore & Co. Inc. IL reduced its position in shares of Biogen Inc. (NASDAQ:BIIB) by 4.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,536 shares of the biotechnology company’s stock after selling 148 shares during the period. Roberts Glore & Co. Inc. IL’s holdings in Biogen were worth $541,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Inspire Trust Co. N.A. raised its holdings in Biogen by 58.5% during the third quarter. Inspire Trust Co. N.A. now owns 10,900 shares of the biotechnology company’s stock worth $2,113,000 after purchasing an additional 4,025 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in Biogen by 0.3% during the fourth quarter. Assenagon Asset Management S.A. now owns 43,460 shares of the biotechnology company’s stock worth $6,646,000 after purchasing an additional 111 shares in the last quarter. Centre Asset Management LLC raised its holdings in Biogen by 7.7% during the fourth quarter. Centre Asset Management LLC now owns 51,530 shares of the biotechnology company’s stock worth $7,880,000 after purchasing an additional 3,698 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Biogen by 1.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 913,029 shares of the biotechnology company’s stock worth $176,982,000 after purchasing an additional 12,319 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in Biogen by 3.2% during the third quarter. Principal Financial Group Inc. now owns 168,631 shares of the biotechnology company’s stock worth $32,687,000 after purchasing an additional 5,270 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Needham & Company LLC reissued a “hold” rating on shares of Biogen in a report on Thursday, February 13th. HC Wainwright dropped their target price on shares of Biogen from $300.00 to $241.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Wolfe Research began coverage on shares of Biogen in a report on Friday, November 15th. They issued a “peer perform” rating for the company. Stifel Nicolaus cut shares of Biogen from a “buy” rating to a “hold” rating and set a $175.00 target price for the company. in a report on Monday, December 16th. Finally, The Goldman Sachs Group dropped their target price on shares of Biogen from $281.00 to $245.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Seventeen analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $213.33.

Biogen Stock Up 2.0 %

Shares of NASDAQ BIIB opened at $150.38 on Friday. Biogen Inc. has a 1 year low of $128.51 and a 1 year high of $238.00. The firm’s 50 day moving average price is $143.98 and its 200 day moving average price is $166.46. The firm has a market cap of $22.01 billion, a P/E ratio of 13.44, a price-to-earnings-growth ratio of 1.51 and a beta of 0.01. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, beating analysts’ consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%. As a group, sell-side analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current year.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.